Global Airway Clearance Devices Market $800 Million by 2029

The global market for airway clearance devices expected to reach $800 million by 2029, growing at a CAGR of 4.4% over the forecast period, driven by increasing prevalence of respiratory diseases such as cystic fibrosis, bronchiectasis, and neuromuscular disorders, growing demand for airway clearance systems as well as handheld devices, and easy access to at home healthcare.

The management of bronchial secretions is one of the main problems encountered in a wide spectrum of medical conditions ranging from respiratory disorders (e.g., COPD, bronchiectasis, cystic fibrosis) to neuromuscular disorders (e.g., ALS) to patients undergoing either thoracic or abdominal surgery. Airway clearance techniques (ACTs), traditionally referred to as chest physiotherapy, are recommended as part of a complex treatment programme for patients with respiratory system diseases.

• The ACTs enhance mucociliary clearance and remove viscous secretions from the airways within the lung to prevent distal airway obstruction. This reduces the infective burden and associated inflammatory effects on the airway epithelia. However, the overall effectiveness of any technique is influenced by several factors closely related to the patient. Adherence to treatment is fundamental and it depends very much on the patient’s satisfaction, motivation and perceived effectiveness.
  • The Mechanical Insufflator/Exsufflator (I/E) device produces changes in the airflow inside the bronchial tree in such a way as to vicariate the cough. It is used mainly in patients with neuromuscular pathologies or respiratory muscle deficiency, who have a hypo valid or ineffective cough.
  • The Percussive Intrapulmonary Ventilation (IPV) device can also provide ventilatory support in patients with neuromuscular disease and in patients with COPD.
  • The High-frequency chest-wall oscillation (HFCWO) or high-frequency chest-wall compression (HFCWC) is a strategy for secretion clearance and decreasing the viscoelasticity of the secretions in various clinical conditions (asthma, COPD, neuromuscular diseases, post-operative patients).

The global market for airway clearance systems research report provides market size ($million 2019 to 2029), market share analysis, growth trends and forecast (CAGR%, 2023 to 2029).

The global market for airway clearance devices segmented by product (positive expiratory pressure device, Flutter mucus clearance device, high frequency chest wall oscillation, intrapulmonary percussive ventilation, others), application [cystic fibrosis, neuromuscular disorders, bronchiectasis, others (immotile cilia syndrome, chronic bronchitis)], end user (hospitals & clinics, home care settings, ambulatory surgical centers, others), and geography.

• Based on the products, the Flutter mucus clearance devices segment accounted for the largest share of the total airway clearance devices market.
  • The Flutter, Turboforte / Pari O-PEP / AirPhysio and PEPE are small handheld device used for airway clearance designed to facilitate clearance of mucus in hypersecretory lung disorders. Exhalation through the Flutter results in oscillations of expiratory pressure and airflow, which vibrate the airway walls (loosening mucus), decrease the collapsibility of the airways, and accelerate airflow, facilitating movement of mucus up the airways.
    • The Flutter is simple to use, inexpensive, and fully portable, and once the patient and family are instructed in its use, it does not require the assistance of a caregiver. For hospitalized patients, elimination of the need for a therapist could reduce health care costs.
• On the other hand, the positive expiratory pressure (PEP) devices segment anticipated to witness the fastest growth rate in the coming years. Breathing out against resistance, in order to achieve positive expiratory pressure (PEP), is applied by many patient groups.
  • Three common indications for PEP are to increase lung volume (Functional Residual Capacity (FRC) and Tidal Volume (VT)), to reduce hyperinflation and to improve airway clearance.

• In terms of applications, the cystic fibrosis segment dominated the revenue share of the global airway clearance products market, as it best meets patients’ needs, and provide comfort, convenience, flexibility, practicality, cost benefits.
  • Cystic fibrosis (CF) is a life-limiting genetic condition in which thick mucus builds up in the lungs, leading to infections, inflammation, and eventually, deterioration in lung function. The airway clearance treatment may significantly improve mucociliary clearance and gas exchange, thereby being of clinical benefit in reducing pulmonary complications in CF patients.
    • ACTs include conventional chest physiotherapy, active cycle of breathing techniques, autogenic drainage, positive expiratory pressure and high-frequency chest compression.
  • However, the bronchiectasis segment expected to register the highest CAGR in the near future. The airway clearance techniques are recommended for people with bronchiectasis both in stable state and during an acute exacerbation.
    • The non-cystic fibrosis bronchiectasis (NCFB / NCFBE), especially during an acute exacerbation, supports the prescription of airway clearance techniques as part of management alongside medical treatment such as oral or intravenous antibiotics and steroids.

The global market for airway clearance devices research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

In addition, the global market for airway clearance systems report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for airway clearance devices and profiled in this report include Adare Pharma Solutions (Aptalis Pharma), Electromed, Inc., General Physiotherapy, Inc., Hill-Rom Holdings, Inc., Philips Respironics, and Thayer Medical Corporation.

• Product
  • Positive Expiratory Pressure (PEP) Device
  • Flutter Mucus Clearance Device
  • High Frequency Chest Wall Oscillation (HFCWO)
  • Intrapulmonary Percussive Ventilation (IPV)
  • Others
• Application
  • Cystic Fibrosis
  • Neuromuscular Disorders
  • Bronchiectasis
  • Others (Immotile Cilia Syndrome, Chronic Bronchitis)
• End User
  • Hospitals & Clinics
  • Home Care Settings
  • Ambulatory Surgical Centers
  • Others
• Geography
  • North America (U.S., Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
  • Asia Pacific (Japan, China, India, Rest of APAC)
  • Latin America (Brazil, Mexico, Rest of LA)
  • Rest of the World
• Company Profiles
  • Adare Pharma Solutions (Aptalis Pharma)
  • Electromed, Inc.
  • General Physiotherapy, Inc.
  • Hill-Rom Holdings, Inc.
  • Philips Respironics
  • Thayer Medical Corporation

To request Table of Contents and Sample Pages of this report:
https://www.ihealthcareanalyst.com/report/airway-clearance-systems-market/

Related publications:

• Global Non-Cystic Fibrosis Bronchiectasis Market $1.3 Billion by 2029
• Electrical Stimulation Devices Market by Product (Spinal Cord Stimulation Devices, Deep Brain Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices, Gastric Electrical Stimulation Devices, Transcutaneous Electrical Nerve Stimulation Devices, Neuromuscular Electrical Stimulation Devices, Other Devices (Electrotherapy Devices, Combination Devices, TNS, TMS), and Applications (Pain Management, Neurological and Movement Disorder Management, Musculoskeletal Disorder Management, Metabolism; GIT Management, Incontinence Management, Esthetics, Training, Wound Healing, Cosmetics) and Forecast 2023-2029
• Sleep Apnea Diagnostic and Therapeutic Devices Market by Product (Diagnostic Devices – Actigraphy Systems, Polysomnography, Respiratory Polygraph, Single Channel Screening Devices (Pulse Oximeters), and Therapeutic Devices (Adaptive Servo Ventilation Systems, Airway Clearance Systems, Positive Airway Pressure Devices, Oral Appliances, Oxygen Devices) and Forecast 2023-2029
• Cystic Fibrosis Drugs Market by Drug Class – Anti-infectives [Arikayce (anikacin liposome inhalation suspension), Tobi Podhaler (tobramycin inhalation powder), Cayston (aztreonam inhalation solution)], CFTR Modulators [Kalydeco (ivacaftor), Orkambi (ivacaftor/lumacaftor), Symdeko (ivacaftor/tezacaftor), Trikafta (elexacaftor/ivacaftor/tezacaftor)], Mucolytic Agents [Pulmozyme (dornase alfa), Hypertonic Saline], PERT [Zenpep/Creon (pancrelipase)], Bronchodilators [Bronchitol (mannitol)] and Forecast 2023-2029
• Noninvasive Ventilation and Airway Management Market by Product [Positive Pressure-Based Noninvasive Ventilation Products, Airway Management Accessories (Heat and Moisture Exchangers, Humidifiers, Nebulizers – Large-Volume Nebulizers, Small-Volume Nebulizers, Nebulizer Compressors)] and Forecast 2023-2029